Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY4066434 |
Synonyms | |
Therapy Description |
Limited information is currently available on LY4066434, a putative KRAS inhibitor (Oct 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY4066434 | LY-4066434|LY 4066434 | KRAS Inhibitor 21 | Limited information is currently available on LY4066434, a putative KRAS inhibitor (Oct 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06607185 | Phase I | Leucovorin Cisplatin Nab-paclitaxel LY4066434 Oxaliplatin Irinotecan Carboplatin Gemcitabine Fluorouracil Cetuximab Pemetrexed Disodium Pembrolizumab | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Recruiting | USA | FRA | ESP | DEU | BEL | 2 |